There MUST be a CGIAR logo or a CRP logo. You can copy and paste the logo you need from the final slide of this presentation. Then you can delete that final slide To replace a photo above, copy and paste this link in your browser: http://www.flickr.com/photos/ilri/sets/72157632057087650/detail/ Find a photo you like and the right size, copy and paste it in the block above.
Development of a subunit vaccine for contagious bovine pleuropneumonia in Africa
Development of a subunit vaccine for
contagious bovine pleuropneumonia in Africa
ILRI BioSciences Day, Nairobi, 27 November 2013
Funding body: IDRC-CIDA (CIFSFR grant)
Full Title: Development of a subunit vaccine for
contagious bovine pleuropneumonia in Africa.
Short Title: Vaccine for CBPP
KARI Vet Res Centre, Muguga
KARI Biotech, Nairobi
Important to ILRI: contribute to the following CGIAR
goal and priorities “Animal health research to develop
low-cost vaccines and diagnostic tools appropriate for
Recipients of outcome: contribution to a better vaccine
will directly benefit livestock keepers in areas with CBPP
and national veterinary services that are responsible for
disease monitoring and vaccination
Howe will it change their lives? Better
productivity, reduced trade restrictions.
State of the problem?
One of the most important
livestock diseases in Africa
Affects 24 m people in low
Distribution of CBPP
How will this project change the outcomes?
A vaccine will reduce the cost of cattle farming and help
to reduce trade restrictions.
Links to ILRI’s SLO’s?
- Reduced rural poverty for the livestock keepers
- Improved food security, as more livestock products are
available at lower cost
Antibodies to proteins from mycoplasma can protect
Use bio-informatics to select 75 potential vaccine
antigens (mycoplasma molecules that are secreted or
present on the surface)
Produce the recombinant proteins
Use these proteins to immunize cattle and check their
capacity to protect the host after challenge.
1.3 (± 0.9)
0.3 (± 0.7)
0.5 (± 0.7)
2.0 (± 2.3)
1. It is possible to induce protection with inactivated
material. Live mycoplasma are not necessary.
2. Protection is not correlated with antibody titre
against whole mycoplasma.
3. The way the antigen is presented and delivered
plays a major role.
If we find that a pool of proteins protect:
- confirm & identify protein
- optimize delivery - adjuvant/doses
- period of immunity
- minimum dose
If we have a potential vaccine:
- roll out and adoption strategy (IDRC-funding)
(together with pox virus project - OVI/Alberta)
What support do you expect from ILRI and the BioScience
I did not expect directorate to do much
but I hope they support to continue this project to the end